Skip to content
The Nexus
DossierENTITY

coronary disease risk

Coverage of coronary disease risk in the Nexus archive.

Earliest in view: Jul 8 · 22:46 UTCMost recent: Jul 8 · 22:46 UTC
Co-mentioned in this coverage
GLP-1 drugstopic1Wegovytopic1Galluporganization1obesity ratestopic1alcohol abusetopic1
Recent coverage
  • HEALTHJul 8 · 22:46 UTCSEMAFOR
    GLP-1 use reaches new high in US

    The use of GLP-1 drugs like Wegovy for weight loss in the US has increased from 3% to 11% in 2024, with an additional 4% reporting past use, per Gallup polling. Obesity rates in the US fell to 36.4% in 2024 from a peak of 39.9% in 2022, and early research suggests these drugs may offer benefits beyond weight loss, including treating alcohol abuse and reducing coronary disease risk.

coronary disease risk · Dossier · The Nexus